Last reviewed · How we verify
Intravitreal Injection
Intravitreal injection is a route of administration that delivers therapeutic agents directly into the vitreous cavity of the eye to treat retinal and posterior segment diseases.
Intravitreal injection is a route of administration that delivers therapeutic agents directly into the vitreous cavity of the eye to treat retinal and posterior segment diseases. Used for Retinal diseases requiring direct intraocular delivery (specific indication not specified in available information).
At a glance
| Generic name | Intravitreal Injection |
|---|---|
| Also known as | Avastin, BEOVU, Eylea, intravitreal bevacizumab |
| Sponsor | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Intravitreal injection bypasses systemic circulation and the blood-retinal barrier, allowing high local concentrations of drugs at the site of disease while minimizing systemic exposure. This delivery method is used for various therapeutic agents including anti-VEGF antibodies, corticosteroids, and other biologics targeting retinal conditions. The specific mechanism depends on the active pharmaceutical ingredient being injected.
Approved indications
- Retinal diseases requiring direct intraocular delivery (specific indication not specified in available information)
Common side effects
- Endophthalmitis
- Retinal detachment
- Cataract progression
- Intraocular pressure elevation
- Vitreous hemorrhage
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) (PHASE2)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
- Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration (PHASE1, PHASE2)
- Safety and Efficacy of Faricimab in Patients With NPDR (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: